On-Demand Webinar Archives

On-Demand Webinar

The Wizard of Oligos: There’s no place like having a successful drug development program!

Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…

CertaraApril 30, 2021

On-Demand Webinar

The Promises and Pitfalls of Gene Therapy for Rare Diseases

The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…

CertaraApril 29, 2021

On-Demand Webinar

Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Part 1: What are oligonucleotide therapeutics, and how do they work?

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Plan to Accelerate Your Time to Drug Submissions

There are common themes driving how quickly you can get from your last database lock…

CertaraApril 20, 2021

On-Demand Webinar

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Pediatric PBPK models have broad application in the drug development process and are being used…

CertaraApril 20, 2021

On-Demand Webinar

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…

CertaraApril 1, 2021

On-Demand Webinar

Strategic Evidence & Value Communication Symposium

Join us on Wednesday, April 21, 2021, from12:00 PM – 2:00 PM EDT for Certara’s…

CertaraMarch 26, 2021

On-Demand Webinar

Purity is a Virtue: A Practical Guide to the Reporting of Impurities

Many pharmaceutical companies struggle with characterizing drug substance (DS) and drug product (DP) impurities and…

CertaraMarch 23, 2021

On-Demand Webinar

The Wizard of Oligos: There’s no place like having a successful drug development program!

The Promises and Pitfalls of Gene Therapy for Rare Diseases

Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations

Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations

Part 1: What are oligonucleotide therapeutics, and how do they work?

Plan to Accelerate Your Time to Drug Submissions

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

Strategic Evidence & Value Communication Symposium

Purity is a Virtue: A Practical Guide to the Reporting of Impurities

Newsletter sign up

Quick links

Solutions

Contact